Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer

ABSTRACT: OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer (NSCLC). METHODS: Patients received cCRT...

Full description

Bibliographic Details

Published in:	Cancer Treatment and Research Communications
Main Authors:	Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quynh-Nhu Nguyen, Michael S O'Reilly, Charles Lu, Frank V Fossella, Ferdinandos Skoulidis, Jianjun Zhang, Anne S Tsao, John V Heymach, George R Blumenschein
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Subjects:	Non-small cell lung cancer KRAS chemoradiotherapy trametinib MEK
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468294222000065